Tumor News and Research

RSS

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics, Inc. today announced new pixantrone end of study follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application currently under review by the European Medicines Agency.

6 Dec 2010

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.

6 Dec 2010

$Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010$

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.

6 Dec 2010

Research reveals new standard treatment options for various forms of lymphoma

The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

Researchers adapt gene chip microarray technology to study glycans

Sugar molecules coat every cell in our bodies and play critical roles in development and disease, yet the components of these "glycans" have been difficult for scientists to study, because of their complexity.

6 Dec 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova Therapeutics announces its late-stage anticancer agent, Estybon- (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010.

4 Dec 2010

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

4 Dec 2010

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

3 Dec 2010

Prostate cancer imaging shows real-time tumor metabolism

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

3 Dec 2010

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

University of Missouri leaders celebrated a nanomedicine milestone today as they announced the creation of a new drug development company. The new company forms a partnership between university researchers and an international pharmaceutical firm to advance testing of a potential cancer treatment created at MU.

3 Dec 2010

MHRA issues notice of acceptance for BioMarin's BMN 673 for genetically-defined cancers

BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for BMN 673 for genetically-defined cancers.

3 Dec 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.

3 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

New clue in leukemia mystery

There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.

2 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Mount Sinai’s instructor receives Liz Tilberis Grant from OCRF

AnaLisa DiFeo, PhD, Instructor in the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, has been honored by the Ovarian Cancer Research Fund (OCRF) with the Liz Tilberis Grant.

2 Dec 2010

Wake Forest University to begin clinical trial for low-grade gliomas

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

2 Dec 2010

LMO1 gene variation can increase neuroblastoma risk

Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. The study team, led by researchers at The Children's Hospital of Philadelphia, found that common variants in the LMO1 gene increase the risk of developing an aggressive form of neuroblastoma, and also mark the gene for continuing to drive the cancer's progression once it forms.

2 Dec 2010

Tumor News and Research

Cell Therapeutics announces new pixantrone EOS follow up results

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Research reveals new standard treatment options for various forms of lymphoma

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Researchers adapt gene chip microarray technology to study glycans

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Research findings could provide breakthrough for development of effective therapies for NSCLC

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Prostate cancer imaging shows real-time tumor metabolism

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

MHRA issues notice of acceptance for BioMarin's BMN 673 for genetically-defined cancers

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

New clue in leukemia mystery

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Mount Sinai’s instructor receives Liz Tilberis Grant from OCRF

Wake Forest University to begin clinical trial for low-grade gliomas

LMO1 gene variation can increase neuroblastoma risk

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News